Fate Therapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:
- Stifel Healthcare Virtual Conference on Tuesday, November 17, 2020 from 4:00-4:30PM ET
- Jefferies Global Healthcare Virtual Conference on Thursday, November 19, 2020 from 9:05-9:35AM ET
- Evercore ISI HealthCONx Virtual Conference on Tuesday, December 1, 2020 from 3:30-3:50PM ET
A live webcast, if recorded, of each presentation will be available through the investor relations section of the Company's website at . Following each live webcast, an archived replay will be available on the Company's website for 30 days.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit .
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
